Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Feb 29, 2008 by Edgar Snyder

New Concerns Arise Over MS Drug Tysabri

Tysabri leads to liver damage

A new warning has been issued about the controversial multiple sclerosis drug Tysabri (natalizumab). U.S. health officials have announced that the medication, manufactured by Biogen Idec and Elan Corporation, can begin causing liver damage within six days of the first dose.

The liver damage caused by Tysabri can be fatal and may result in the need for a liver transplant. Use of the drug should be stopped if patients become jaundiced or have other evidence of liver damage.

This is not the first time that the adverse effects of Tysabri have been in the spotlight. The drug first received approval from the U.S. Food and Drug Administration (FDA) in November 2004, but was pulled from the market three months later after several patients in clinical trials developed a deadly viral infection of the brain called progressive multifocal leukoencephalopathy. In June 2006, the FDA allowed the drug back on the market but with strict administration guidelines.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Maryland, Ohio, Virginia, and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation may involve co-counsel.

Sources:
"Tysabri May Cause Liver Damage, Health Officials Say." The Washington Post. February 27, 2008.
FDA Safety Alert. February 27, 2008.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 30, 2016
September Mocktail: Apple Pie Punch
Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Tweet